References
- Justin T, Suzanne M, Brent C, et al. Richard Beasley External validity of randomized controlled trials in COPD. Respir Med. 2007;101:1313–1320. doi:10.1016/j.rmed.2006.10.011
- van Dijk M, Gan CT, Koster TD, et al. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Res. 2020;6:00322–2019. doi:10.1183/23120541.00322-2019
- Bhatt SP, Rabe KF, Hanania NA, et al. BOREAS investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389:205–214. doi:10.1056/NEJMoa2303951
- Kuzma AM, Meli Y, Meldrum C, et al. Multidisciplinary care of the patient with chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:567–571. doi:10.1513/pats.200708-125ET
- Hurst JR, Winders T, Worth H, et al. A patient charter for chronic obstructive pulmonary disease. Adv Ther. 2021;38:11–23. doi:10.1007/s12325-020-01577-7
- Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;2022:1
- van der Valk JPM, Kappen JH, van Campen JSJA, et al. Roadmap to improve regional care for patients with severe asthma. Clin Transl Allergy. 2021;11:1. doi:10.1002/clt2.12080